GlobeNewswire: Dynavax Technologies Corporation Contains the last 10 of 316 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:38:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/08/31/2086453/0/en/Dynavax-to-Present-at-the-H-C-Wainwright-Virtual-22nd-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=43704Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference2020-08-31T20:10:00Z<![CDATA[EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on Monday, September 14, at 10:00 a.m. ET.]]>https://www.globenewswire.com/news-release/2020/08/13/2077857/0/en/Dynavax-Announces-Grant-to-Scale-up-CpG-1018-Adjuvant-Capacity-to-Support-the-Global-COVID-19-Response.html?f=22&fvtc=4&fvtv=43704Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response2020-08-13T12:00:00Z<![CDATA[EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant doses annually, which can be further increased if needed.]]>https://www.globenewswire.com/news-release/2020/08/06/2074569/0/en/Dynavax-Announces-Second-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=43704Dynavax Announces Second Quarter 2020 Financial Results2020-08-06T20:02:00Z<![CDATA[EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter of 2020.]]>https://www.globenewswire.com/news-release/2020/08/03/2071659/0/en/TriSalus-Life-Sciences-Acquires-Dynavax-s-SD-101-Oncology-Program-in-Purchase-Agreement-for-up-to-250-million-in-Milestone-Payments-plus-Royalties-on-Future-Net-Sales.html?f=22&fvtc=4&fvtv=43704TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales2020-08-03T12:00:00Z<![CDATA[WESTMINSTER, Colo. and EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for liver and pancreatic tumors, today announced that they have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide, which has been studied in advanced cutaneous melanoma, and is currently in clinical trials for high risk Stage II/III breast cancer. Purchased assets include SD-101-related Intellectual Property, clinical data, regulatory filings, and inventory.]]>https://www.globenewswire.com/news-release/2020/07/30/2070692/0/en/Dynavax-to-Report-Second-Quarter-2020-Financial-Results-and-Host-Conference-Call-on-August-6-2020.html?f=22&fvtc=4&fvtv=43704Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 20202020-07-30T20:05:00Z<![CDATA[EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close.]]>https://www.globenewswire.com/news-release/2020/07/23/2066551/0/en/Dynavax-and-Medigen-Announce-Collaboration-to-Develop-a-Novel-Adjuvanted-COVID-19-Vaccine-Candidate.html?f=22&fvtc=4&fvtv=43704Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate2020-07-23T12:00:00Z<![CDATA[EMERYVILLE, Calif. and TAPEI, Taiwan, July 23, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, today announced their collaboration to develop an adjuvanted vaccine candidate to protect against COVID-19. The collaboration is evaluating the combination of MVC’s stable prefusion form of the SARS-CoV2 recombinant spike protein with Dynavax’s advanced adjuvant CpG 1018™, the adjuvant contained in Dynavax’s U.S. FDA-approved adult hepatitis B vaccine.]]>https://www.globenewswire.com/news-release/2020/07/21/2065318/0/en/Dynavax-Announces-the-Appointment-of-Two-New-Board-Members.html?f=22&fvtc=4&fvtv=43704Dynavax Announces the Appointment of Two New Board Members2020-07-21T20:10:00Z<![CDATA[EMERYVILLE, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Ms. Julie Eastland and Mr. Brent MacGregor to its Board of Directors.]]>https://www.globenewswire.com/news-release/2020/07/16/2063341/0/en/Dynavax-and-Mount-Sinai-Announce-Collaboration-to-Develop-a-Universal-Influenza-Vaccine-Candidate-with-CpG-1018-Adjuvant.html?f=22&fvtc=4&fvtv=43704Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant2020-07-16T12:40:00Z<![CDATA[NEW YORK and EMERYVILLE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) today announced they have entered into a collaboration to develop a universal influenza (flu) vaccine. Mount Sinai’s current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program established by NIAID. The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin (cHA) designed to protect against all strains of influenza in combination with Dynavax’s CpG 1018TM adjuvant.]]>https://www.globenewswire.com/news-release/2020/07/14/2061854/0/en/Dynavax-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-Evaluating-Medicago-s-COVID-19-Vaccine-Candidate-with-Dynavax-s-CpG-1018-Adjuvant.html?f=22&fvtc=4&fvtv=43704Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant2020-07-14T12:00:00Z<![CDATA[EMERYVILLE, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, announced today that the first participants have been dosed in the Phase 1 clinical trial evaluating Medicago’s plant-derived vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19.]]>https://www.globenewswire.com/news-release/2020/07/10/2060788/0/en/Dynavax-and-Times-Pharmacy-Announce-Partnership-to-Offer-HEPLISAV-B-Hepatitis-B-Vaccine-to-Customers-Throughout-Oahu-with-a-Focus-on-People-with-Diabetes.html?f=22&fvtc=4&fvtv=43704Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes2020-07-10T20:01:00Z<![CDATA[- People with diabetes are two times more likely to become infected with the hepatitis B virus (HBV) and up to four times as likely to get HBV-related liver cancer]]>